Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management
The Journal of Thoracic and Cardiovascular Surgery · 2026-07 · 172 (1) · 32-42.e8
DOI: 10.1016/j.jtcvs.2026.02.017 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2026-07. Verfasst von Chang Yuan und 30 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Department of Thoracic Surgery, Shanghai Chest Hospi…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Neoplasm Recurrence, Local, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Shanghai Hospital Development Center, National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: Pathologic complete response (pCR) after neoadjuvant therapy predicts favorable outcomes in esophageal squamous cell carcinoma (ESCC). In this era of neoadjuvant immunochemotherapy (nICT), the prognosis of patients achieving nICT-induced pCR remains unclear. This study aimed to characterize recurrence patterns and identify prognostic factors in this population. METHODS: A multicenter retrospective cohort study was conducted across 26 Chinese centers from 2019 to 2023. Patients with ESCC who underwent surgery after nICT and achieved pCR were included. Prognostic factors for recurrence-free survival (RFS) and overall survival (OS) were evaluated using Cox regression analysis. RESULTS: Among 2135 patients receiving nICT, 474 (22.2%) achieved pCR. After a median follow-up of 32.8 months, 60 patients (12.7%) experienced recurrence, with a median interval of 17.8 months (interquartile range, 8.7-26.7) after surgery. Most recurrences (75%) occurred within 2 years, predominantly as distant metastases (63.3%), with the lung being the most common site. The 2-year RFS and OS were 89.6% and 92.1%, respectively. Advanced clinical nodal stage (cN2-3) was identified as an independent prognostic factor for inferior RFS (adjusted hazard ratio, 1.83; 95% CI, 1.10-3.05; P = .02) but not OS, whereas adjuvant treatment was not associated with improved survival (adjusted hazard ratio, 1.29; 95% CI, 0.69-2.42; P = .42). CONCLUSIONS: Patients with ESCC achieving pCR after nICT exhibited excellent short-term survival but a persistent risk of distant recurrence. Advanced clinical nodal stage is associated with higher recurrence risk, which warrants further validation. Risk-adapted postoperative management may be preferable to routine adjuvant treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R.…
- Department of Thoracic Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai, P.R. China.
- Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union M…
- Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China.
- Department of Thoracic Surgery, Hunan Cancer Hospital, Changsha, P.R. China.
- Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, P.R. China.
Förderung
- Shanghai Hospital Development Center
- National Natural Science Foundation of China
Zitieren
APA
Yuan, C., Chen, C., Liu, Z., Tan, L., Li, Y., Tian, Z., Chen, Y., Ma, J., Liu, S., Chen, C., Han, Y., Chen, L., Yu, B., Jiang, T., Li, X., Wang, W., Wei, L., Chen, Q., Zhao, J., …, & Esophageal Cancer Committee of Chinese Anti-Cancer Association (CACA) (2026). Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management. The Journal of Thoracic and Cardiovascular Surgery, 172(1), 32-42.e8. https://doi.org/10.1016/j.jtcvs.2026.02.017
Vancouver
Yuan C, Chen C, Liu Z, Tan L, Li Y, Tian Z, et al. Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management. The Journal of Thoracic and Cardiovascular Surgery. 2026;172(1):32-42.e8. doi:10.1016/j.jtcvs.2026.02.017
BibTeX
@article{Yuan2026,
author = {Yuan, Chang and Chen, Chunji and Liu, Zhichao and Tan, Lijie and Li, Yin and Tian, Ziqiang and Chen, Yuejun and Ma, Jianqun and Liu, Shuoyan and Chen, Chun and Han, Yongtao and Chen, Longqi and Yu, Bentong and Jiang, Tao and Li, Xiangnan and Wang, Weijie and Wei, Li and Chen, Qixun and Zhao, Jianqiang and Fu, Junhui and Tian, Hui and Ma, Yegang and Yi, Jun and Hu, Weidong and Zhang, Guangjian and Lian, Jianhong and Mei, Xinyu and Chen, Keneng and Mao, Yousheng and Li, Zhigang and Esophageal Cancer Committee of Chinese Anti-Cancer Association (CACA), Esophageal Cancer Committee of Chinese Anti-Cancer Association (CACA)},
title = {Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2026},
volume = {172},
number = {1},
pages = {32--42.e8},
doi = {10.1016/j.jtcvs.2026.02.017}
}
EUVIMED